ALX ONCOLOGY HOLDINGS INC Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount
ALX ONCOLOGY HOLDINGS INC (ALXO) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount of $4.03 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-09.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2026-03-09
- ALX ONCOLOGY HOLDINGS INC effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2025 was $4.03M, a 180.25% increase from fiscal 2024.
- ALX ONCOLOGY HOLDINGS INC effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2024 was $1.44M, a 60.27% decline from fiscal 2023.
- ALX ONCOLOGY HOLDINGS INC effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2023 was $3.62M, a 52.83% increase from fiscal 2022.
- ALX ONCOLOGY HOLDINGS INC effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2022 was $2.37M.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $4.03M 10-K · filed 2026-03-09 | |
| 2024-12-31 | $1.44M 10-K · filed 2026-03-09 | $1.45M 10-K · filed 2025-03-06 |
| 2023-12-31 | $3.62M 10-K · filed 2026-03-09 | $3.65M 10-K · filed 2024-03-07 |
| 2022-12-31 | $2.37M 10-K · filed 2025-03-06 | |
| 2021-12-31 | -$4.03M 10-K · filed 2024-03-07 | |
| 2020-12-31 | -$5.00K 10-K · filed 2023-03-09 | |
| 2019-12-31 | $60.00K 10-K · filed 2022-02-28 | |
| 2018-12-31 | $57.00K 10-K · filed 2021-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |